Value
6.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 9.9 |
| Analyst target | 4.0 |
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Myriad Genetics is a shrinking, unprofitable diagnostics company whose stock has rallied well above the analyst target, with falling estimates and a likely earnings test in 3 days making the rally hard to defend.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
| Pillar | Expectation | Trend |
|---|---|---|
The stock at $6.35 is above the $3.90 analyst target, with a distance to target of -38.5% and a reward-to-risk of -2.57. Analyst target | Analyst targets should rise toward the price, or the price should retrace toward the target, over the next 12 months. | ↑Improving |
| CounterThe price rally from momentum and rising on-balance volume may be telling us analysts are slow to update a target that has become stale. | ||
Revenue is declining 10%, the Rule of 40 reads -8, and quality scores 3.5/10 with no competitive moat. Quality breakdown | Revenue should return to growth above 0% and the Rule of 40 score should rise above 0 within 12 months. | →Stable |
| CounterThe company is free-cash-flow positive despite a GAAP loss (FCF yield 3.0%) and gross margin scores 9.8/10, so the economics may be better than the loss suggests. | ||
EPS missed in 2 of the last 3 reported quarters, the latest at -$0.25 against a -$0.06 estimate, and the next report is due in 3 days. Earnings | EPS should come in at or better than estimates in the upcoming report and the following quarters. | ↓Deteriorating |
| CounterThe February report beat by $0.06 and surprise averages are skewed by small per-share numbers, so the misses may be noise. | ||
Earnings estimates fell 5.1% over 30 days, and the sentiment score for the price target component is only 1.5/10. Catalyst breakdown | Estimate revisions should turn positive within the next two quarters. | ↓Deteriorating |
| CounterEstimates fall before many turnarounds, and with institutions accumulating, lower expectations may set up easier comparisons. | ||
The momentum score is 6.3/10 but RSI is 79 and the 200-day average slope is flat to negative, a late-stage rally with distribution risk. Momentum breakdown | RSI should cool below 70 without the price falling below its 200-day average. | ↓Deteriorating |
| CounterOn-balance volume is rising and the MACD component is 9.9, showing buyers are still in control of the trend. | ||
CounterThe price rally from momentum and rising on-balance volume may be telling us analysts are slow to update a target that has become stale.
CounterThe company is free-cash-flow positive despite a GAAP loss (FCF yield 3.0%) and gross margin scores 9.8/10, so the economics may be better than the loss suggests.
CounterThe February report beat by $0.06 and surprise averages are skewed by small per-share numbers, so the misses may be noise.
CounterEstimates fall before many turnarounds, and with institutions accumulating, lower expectations may set up easier comparisons.
CounterOn-balance volume is rising and the MACD component is 9.9, showing buyers are still in control of the trend.
| Component | Sub-score |
|---|---|
| P/S | 9.9 |
| Analyst target | 4.0 |
| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 9.7 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 6.9 |
| FCF quality | 3.1 |
| Moat | 4.8 |
| Rule of 40 | 3.0 |
| Piotroski F | 4.4 |
| Component | Sub-score |
|---|---|
| Rev growth | 2.1 |
| Component | Sub-score |
|---|---|
| RSI | 7.9 |
| MACD | 1.4 |
| OBV | 1.0 |
| MA position | 5.0 |
| Volume | 0.0 |
| Component | Sub-score |
|---|---|
| LLM sentiment | 7.0 |
| Analyst rating | 5.0 |
| Price target | 5.9 |
| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
| Component | Sub-score |
|---|---|
| value rank | 9.7 |
| quality rank | 1.3 |
| growth rank | 1.0 |
| Component | Sub-score |
|---|---|
| bollinger | 7.7 |
| support resistance | 7.9 |
| 52w position | 3.0 |
| gap | 6.0 |
| Component | Sub-score |
|---|---|
| short interest | 5.5 |
| days to cover | 8.0 |
| volatility | 0.0 |
| put call | 0.0 |
| max pain risk | 7.0 |
| beta | 4.6 |
| debt equity | 6.3 |
| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 5.7 |
| news activity | 6.0 |
Quality below minimum threshold.
L1:HARD_BLOCK:QUALITY_FLOORSetup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — Beta 1.61>1.3, MCap $0.5B<$5B
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.1<4.5 outcome against Insider at 7.3 and asymmetric R:R of -0.60.
The strongest dimensions are Insider at 7.3, Value at 6.4, and Technical at 6.2; the weakest are Growth at 2.1, Momentum at 3.1, and Quality at 3.2. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of -0.60 and an engine sizing output of AVOID.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
Trip ifAnalyst target rises above $6.67 so that upside exceeds 5% from the current -38.5%.
Trip ifRevenue growth exceeds 0% YoY versus the current -10%.
Trip ifEPS surprise exceeds 0% for 2 consecutive quarters.
Trip ifEarnings estimates rise more than 5% over 30 days, reversing the current -5.1%.
Trip ifMomentum score falls below 4.5 from the current 6.3 while the price drops more than 10%.